Patent Term Extension: The Complete PTE Calculation and Regulatory Review Period Playbook
1. Why PTE Is a Financial Asset, Not an Administrative Checkbox A single additional day of patent exclusivity on Keytruda […]
KSM Sourcing for Pharmaceutical APIs: The Definitive Playbook
Executive Summary Three decades of aggressive outsourcing to low-cost geographies suppressed the Cost of Goods Sold (COGS) for Active Pharmaceutical
KSM Sourcing for Pharmaceutical APIs: The Definitive Playbook Read Post »
Turning Pharmaceutical Patent Expirations into Competitive Advantage: A Complete IP Strategy and Market Intelligence Guide
Section 1: The Patent Cliff, Defined and Reframed What the Term Actually Means The phrase ‘patent cliff’ describes the sharp
How to Conduct a Rigorous Generic Drug Market Analysis: The Complete Practitioner’s Guide
Why Generic Drug Market Analysis Fails — and How to Fix It Most generic drug market analyses make the same
REMS Weaponized: How Brand Pharma Turns Safety Programs Into $13.4B Competition Shields
A deep-dive pillar for pharma IP teams, generic market strategists, portfolio managers, and institutional investors tracking ANDA timelines and biosimilar
REMS Weaponized: How Brand Pharma Turns Safety Programs Into $13.4B Competition Shields Read Post »
Machine Learning in Drug Discovery: The Definitive Technical and Strategic Guide for Pharma IP Teams, R&D Leaders, and Institutional Investors
1. Eroom’s Law, the $2.6 Billion Problem, and Why Traditional R&D Has Stopped Working Jack Scannell named Eroom’s Law in
Win the Generic Drug Market: Patents, ANDAs, IP Valuation, and the Tactics That Separate First-Movers from Also-Rans
Executive Summary The global generic drug market sits at an unusual intersection: structural demand that will not shrink, a near-term
Build a Generic Drug Portfolio That Actually Makes Money: The Complete Competitive Intelligence Playbook
The generic pharmaceutical industry has a problem it created for itself. For decades, the dominant growth strategy was volume: file
REMS Abuse: How Brand Pharma Turned Patient Safety Rules Into a $5.4 Billion Competitive Weapon
There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a
